Algeta demonstrates radioimmunotherapeutic potential of a tumor-targeting monoclonal antibody labeled with Thorium-227
While these initial observations have been made with a mAb already indicated for relapsed or refractory non-Hodgkin's lymphoma, Algeta anticipates this study having broader implications for mAb-alpha emitter conjugates in a therapeutic setting. In particular, given the known affinity of selected alpha-emitting nuclides for skeletal tissues to which a number of solid tumors metastasize, mAb-directed approaches would appear to have therapeutic potential even in advanced stages of cancer.
In view of these results, Algeta is now seeking partner companies committed to the development and commercialization of alpha-particle emitting mAbs as products for the treatment of primary and advanced cancer conditions.
Original publication: J. Dahle et al.; Nuclear Medicine and Biology 2006, 33, 271-279.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous